News & Updates
Filter by Specialty:
Deuruxolitinib helps restore crowning glory in alopecia areata
Pooled analyses of the phase III THRIVEAA1 and THRIVE-AA2 trials underpin the potential of the selective oral JAK* 1/2 inhibitor deuruxolitinib to effectively and safely reverse hair loss in adults with moderate-to-severe alopecia areata (AA).
Deuruxolitinib helps restore crowning glory in alopecia areata
25 Mar 2024
Lebrikizumab plus TCS improves outcomes in moderate-to-severe AD
Treatment with lebrikizumab in combination with topical corticosteroids (TCS), compared with TCS alone, results in early and sustained improvements in patient-reported outcomes (PROs) among individuals with moderate-to-severe atopic dermatitis (AD), as shown in a Japan study.
Lebrikizumab plus TCS improves outcomes in moderate-to-severe AD
23 Mar 2024
ESK-001 makes good STRIDEs for plaque psoriasis
In the phase II dose-ranging STRIDE trial presented at AAD 2024, ESK-001, a highly-selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor, demonstrated favourable efficacy and safety signals for the treatment of adults with moderate-to-severe plaque psoriasis.
ESK-001 makes good STRIDEs for plaque psoriasis
22 Mar 2024
Dupilumab mends skin barrier in children with AD, but with caveat
Use of dupilumab results in normalization of stratum corneum (SC) lipids, which is responsible for skin barrier function, in children with atopic dermatitis (AD) within 1 to 2 months of treatment, according to a study presented at AAAAI 2024.
